Spirocyclic amides as cannabinoid receptor modulators

Details Spirocyclic amides as cannabinoid receptor modulators Spirocyclic amides as cannabinoid receptor modulators

C - Chemistry, Metallurgy

07

C

C07C 233/13 (2006.01) A61K 31/16 (2006.01) A61P 3/04 (2006.01) C07C 233/57 (2006.01) C07C 233/59 (2006.01) C07C 235/40 (2006.01) C07C 235/82 (2006.01) C07C 237/24 (2006.01) C07C 255/60 (2006.01) C07C 271/24 (2006.01) C07C 317/44 (2006.01) C07D 205/00 (2006.01) C07D 205/04 (2006.01) C07D 207/08 (2006.01) C07D 207/16 (2006.01) C07D 207/48 (2006.01) C07D 211/30 (2006.01) C07D 211/32 (2006.01) C07D 211/60 (2006.01) C07D 211/62 (2006.01) C07D 211/68 (2006.01) C07D 211/80 (2006.01) C07D 213/56 (2006.01) C07D 213/

Patent

CA 2479618

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Selon la présente invention, les nouveaux composés de formule structurale (I) sont des antagonistes et/ou des agonistes inverses du récepteur cannabinoïde 1 (CB1) et sont utiles dans le traitement, la prévention et la suppression de maladies induites par le récepteur CB1. Les composés selon la présente invention sont utiles en tant que médicaments psychotropes pour traiter la psychose, les déficiences de la mémoire, les troubles cognitifs, la migraine, la neuropathie, les troubles neuro-inflammatoires tels que la sclérose en plaques et le syndrome de Guillain-Barré, les séquelles inflammatoires de l'encéphalite virale, les accidents vasculaires cérébraux et le traumatisme crânien, les troubles de l'anxiété, le stress, l'épilepsie, la maladie de Parkinson, les troubles du déplacement et la schizophrénie. Lesdits composés sont également utilisés pour traiter les troubles liés à l'abus de substances psychoactives, pour traiter l'obésité ou les troubles de l'alimentation, ainsi que pour traiter l'asthme, la constipation, la pseudo-obstruction intestinale chronique et la cirrhose du foie.

Affiliated with

Also associated with

Rating

Spirocyclic amides as cannabinoid receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Spirocyclic amides as cannabinoid receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spirocyclic amides as cannabinoid receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2045914